1. Home
  2. ARTV vs BAFN Comparison

ARTV vs BAFN Comparison

Compare ARTV & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTV
  • BAFN
  • Stock Information
  • Founded
  • ARTV 2019
  • BAFN 1999
  • Country
  • ARTV United States
  • BAFN United States
  • Employees
  • ARTV N/A
  • BAFN N/A
  • Industry
  • ARTV
  • BAFN Savings Institutions
  • Sector
  • ARTV
  • BAFN Finance
  • Exchange
  • ARTV NYSE
  • BAFN Nasdaq
  • Market Cap
  • ARTV 61.9M
  • BAFN 61.9M
  • IPO Year
  • ARTV 2024
  • BAFN N/A
  • Fundamental
  • Price
  • ARTV $2.08
  • BAFN $15.79
  • Analyst Decision
  • ARTV Strong Buy
  • BAFN
  • Analyst Count
  • ARTV 7
  • BAFN 0
  • Target Price
  • ARTV $20.00
  • BAFN N/A
  • AVG Volume (30 Days)
  • ARTV 215.6K
  • BAFN 10.1K
  • Earning Date
  • ARTV 05-08-2025
  • BAFN 04-24-2025
  • Dividend Yield
  • ARTV N/A
  • BAFN 2.02%
  • EPS Growth
  • ARTV N/A
  • BAFN 113.18
  • EPS
  • ARTV N/A
  • BAFN 2.34
  • Revenue
  • ARTV N/A
  • BAFN $80,167,000.00
  • Revenue This Year
  • ARTV N/A
  • BAFN N/A
  • Revenue Next Year
  • ARTV N/A
  • BAFN N/A
  • P/E Ratio
  • ARTV N/A
  • BAFN $6.75
  • Revenue Growth
  • ARTV N/A
  • BAFN 2.60
  • 52 Week Low
  • ARTV $1.78
  • BAFN $10.40
  • 52 Week High
  • ARTV $17.31
  • BAFN $19.75
  • Technical
  • Relative Strength Index (RSI)
  • ARTV N/A
  • BAFN 51.59
  • Support Level
  • ARTV N/A
  • BAFN $15.42
  • Resistance Level
  • ARTV N/A
  • BAFN $17.45
  • Average True Range (ATR)
  • ARTV 0.00
  • BAFN 0.86
  • MACD
  • ARTV 0.00
  • BAFN 0.22
  • Stochastic Oscillator
  • ARTV 0.00
  • BAFN 53.89

About ARTV ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: